T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The primary goal is to determine the maximum tolerated dose (MTD) of the combination of T-DM1
and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously
treated with taxanes and trastuzumab-based therapy.
In addition, pharmacokinetic data on the combination of T-DM1 and lyposomal doxorubicin will
be obtained.